Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX-2 Versus COX-1 in Healthy Subjects by Schwartz, Jules I., Dallob, Aimee L., Larson, Patrick J., Laterza, Omar F., Miller, Jutta, Royalty, Jane, Snyder, Karen M., Chappell, Derek L., Hilliard, Deborah A., Flynn, Mary E., Cavanaugh Jr, Paul F., Wagner, John A.

Get full text

Synthesis and structure-activity relationships of a novel class of 5-lipoxygenase inhibitors. 2-(Phenylmethyl)-4-hydroxy-3,5-dialkylbenzofurans: the development of L-656,224 by Lau, Cheuk K, Belanger, Patrice C, Scheigetz, John, Dufresne, Claude, Williams, Haydn W. R, Maycock, Alan L, Guindon, Yvan, Bach, Thomas, Dallob, Aimee L

Get full text

Measurement of Plasma Angiotensin II: Purification by Cation-Exchange Chromatography by Ledwith, B.J., Cahill, M.K., Losse, L.S., Satiritz, S.M., Eydelloth, R.S., Dallob, A.L., Tanaka, W.K., Galloway, S.M., Nichols, W.W.

Get full text

High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid by Hendrickson, Ronald C, Lee, Anita Y H, Song, Qinghua, Liaw, Andy, Wiener, Matt, Paweletz, Cloud P, Seeburger, Jeffrey L, Li, Jenny, Meng, Fanyu, Deyanova, Ekaterina G, Mazur, Matthew T, Settlage, Robert E, Zhao, Xuemei, Southwick, Katie, Du, Yi, Holder, Dan, Sachs, Jeffrey R, Laterza, Omar F, Dallob, Aimee, Chappell, Derek L, Snyder, Karen, Modur, Vijay, King, Elizabeth, Joachim, Catharine, Bondarenko, Andrey Y, Shearman, Mark, Soper, Keith A, Smith, A David, Potter, William Z, Koblan, Ken S, Sachs, Alan B, Yates, Nathan A

Get full text

Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers by van Hecken, Anne, Schwartz, Jules I., Depré, Marleen, de Lepeleire, Inge, Dallob, Aimee, Tanaka, Wesley, Wynants, Kathleen, Buntinx, Agnes, Arnout, Jef, Wong, Peggy H., Ebel, David L., Gertz, Barry J., de Schepper, Paul J.

Get full text

Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor by Dallob, Aimee, Hawkey, Christopher J., Greenberg, Howard, Wight, Nicholas, De Schepper, Paul, Waldman, Scott, Wong, Peggy, DeTora, Lisa, Gertz, Barry, Agrawal, Nancy, Wagner, John, Gottesdiener, Keith

Get full text

The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia by Drake, Lynn, Hordinsky, Maria, Fiedler, Virginia, Swinehart, James, Unger, Walter P., Cotterill, Paul C., Thiboutot, Diane M., Lowe, Nicholas, Jacobson, Coleman, Whiting, David, Stieglitz, Sam, Kraus, Stephen J., Griffin, Edmond I., Weiss, Darryl, Carrington, Patrick, Gencheff, Christopher, Cole, Gary W., Pariser, David M., Epstein, Edwin S., Tanaka, Wesley, Dallob, Aimée, Vandormael, Kristel, Geissler, Lori, Waldsteicher, Joanne

Get full text

MK-386, an inhibitor of 5α-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen by SCHWARTZ, J. I, TANAKA, W. K, WANG, D. Z, EBEL, D. L, GEISSLER, L. A, DALLOB, A, HAFKIN, B, GERTZ, B. J

Get full text

MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen 1 by Schwartz, Jules I., Tanaka, Wesley K., Wang, Daniel Z., Ebel, David L., Geissler, Lori A., Dallob, Aimee, Hafkin, Barry, Gertz, Barry J.

Get full text

MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen1 by Schwartz, Jules I, Tanaka, Wesley K, Wang, Daniel Z, Ebel, David L, Geissler, Lori A, Dallob, Aimee, Hafkin, Barry, Gertz, Barry J

Get full text